228 related articles for article (PubMed ID: 25350082)
1. In vitro profiling of the metabolism and drug-drug interaction of tofogliflozin, a potent and highly specific sodium-glucose co-transporter 2 inhibitor, using human liver microsomes, human hepatocytes, and recombinant human CYP.
Yamane M; Kawashima K; Yamaguchi K; Nagao S; Sato M; Suzuki M; Honda K; Hagita H; Kuhlmann O; Poirier A; Fowler S; Funk C; Simon S; Aso Y; Ikeda S; Ishigai M
Xenobiotica; 2015 Mar; 45(3):230-8. PubMed ID: 25350082
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and mass balance of SGLT2 inhibitor tofogliflozin following oral administration to humans.
Zell M; Husser C; Kuhlmann O; Schwab D; Uchimura T; Kemei T; Kawashima K; Yamane M; Pähler A
Xenobiotica; 2014 Apr; 44(4):369-78. PubMed ID: 24074237
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the in vitro and in vivo metabolic pathway and cytochrome P450 inhibition/induction profile of Huperzine A.
Lin PP; Li XN; Yuan F; Chen WL; Yang MJ; Xu HR
Biochem Biophys Res Commun; 2016 Nov; 480(2):248-253. PubMed ID: 27751854
[TBL] [Abstract][Full Text] [Related]
4. A Pharmacokinetic/Pharmacodynamic Drug-Drug Interaction Study of Tofogliflozin (a New SGLT2 Inhibitor) and Selected Anti-Type 2 Diabetes Mellitus Drugs.
Kasahara N; Fukase H; Ohba Y; Saito T; Miyata K; Iida S; Takano Y; Ikeda S; Harigai M; Terao K
Drug Res (Stuttg); 2016 Feb; 66(2):74-81. PubMed ID: 26158794
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction.
Kumar G; Lau H; Laskin O
Cancer Chemother Pharmacol; 2009 May; 63(6):1171-5. PubMed ID: 19030860
[TBL] [Abstract][Full Text] [Related]
6. In vitro oxidative metabolism of cajaninstilbene Acid by human liver microsomes and hepatocytes: involvement of cytochrome p450 reaction phenotyping, inhibition, and induction studies.
Hua X; Peng X; Tan S; Li C; Wang W; Luo M; Fu Y; Zu Y; Smyth H
J Agric Food Chem; 2014 Oct; 62(43):10604-14. PubMed ID: 25272989
[TBL] [Abstract][Full Text] [Related]
7. In vitro inhibition and induction of human cytochrome P450 enzymes by mirabegron, a potent and selective β3-adrenoceptor agonist.
Takusagawa S; Miyashita A; Iwatsubo T; Usui T
Xenobiotica; 2012 Dec; 42(12):1187-96. PubMed ID: 22834478
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of In Vitro Cytochrome P450 Inhibition and In Vitro Fate of Structurally Diverse N-Oxide Metabolites: Case Studies with Clozapine, Levofloxacin, Roflumilast, Voriconazole and Zopiclone.
Giri P; Naidu S; Patel N; Patel H; Srinivas NR
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):677-688. PubMed ID: 27853934
[TBL] [Abstract][Full Text] [Related]
9. In vitro assessment of cytochrome P450 inhibition and induction potential of felotaxel (SHR110008).
Ding Y; Jia Y; Lu C; Liu W; Yang J; Song Y; Zhu Y; Yang L; Ding L; Wen A
Biomed Pharmacother; 2012 Jun; 66(4):318-21. PubMed ID: 22397757
[TBL] [Abstract][Full Text] [Related]
10. Metabolism-mediated drug interaction potential of HS-23, a new herbal drug for the treatment of sepsis in human hepatocytes and liver microsomes.
Jeong HU; Lee JY; Kwon SS; Kim JH; Kim YM; Hong SW; Yeon SH; Lee SM; Cho YY; Lee HS
Arch Pharm Res; 2015 Feb; 38(2):171-7. PubMed ID: 25052959
[TBL] [Abstract][Full Text] [Related]
11. In vitro evaluation of the interaction potential of irosustat with drug-metabolizing enzymes.
Ventura V; Solà J; Peraire C; Brée F; Obach R
Drug Metab Dispos; 2012 Jul; 40(7):1268-78. PubMed ID: 22451700
[TBL] [Abstract][Full Text] [Related]
12. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes.
Parkinson A; Mudra DR; Johnson C; Dwyer A; Carroll KM
Toxicol Appl Pharmacol; 2004 Sep; 199(3):193-209. PubMed ID: 15364537
[TBL] [Abstract][Full Text] [Related]
13. In vitro assessment of cytochrome P450 inhibition and induction potential of tanespimycin and its major metabolite, 17-amino-17-demethoxygeldanamycin.
Gan J; Liu-Kreyche P; Humphreys WG
Cancer Chemother Pharmacol; 2012 Jan; 69(1):51-6. PubMed ID: 21594721
[TBL] [Abstract][Full Text] [Related]
14. A novel double-tracer technique to characterize absorption, distribution, metabolism and excretion (ADME) of [14C]tofogliflozin after oral administration and concomitant intravenous microdose administration of [13C]tofogliflozin in humans.
Schwab D; Portron A; Backholer Z; Lausecker B; Kawashima K
Clin Pharmacokinet; 2013 Jun; 52(6):463-73. PubMed ID: 23494983
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and related human risk factors for hepatic damage by usnic acid containing nutritional supplements.
Foti RS; Dickmann LJ; Davis JA; Greene RJ; Hill JJ; Howard ML; Pearson JT; Rock DA; Tay JC; Wahlstrom JL; Slatter JG
Xenobiotica; 2008 Mar; 38(3):264-80. PubMed ID: 18274956
[TBL] [Abstract][Full Text] [Related]
16. Stereoselective metabolism of cibenzoline, an antiarrhythmic drug, by human and rat liver microsomes: possible involvement of CYP2D and CYP3A.
Niwa T; Shiraga T; Mitani Y; Terakawa M; Tokuma Y; Kagayama A
Drug Metab Dispos; 2000 Sep; 28(9):1128-34. PubMed ID: 10950860
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of novel C-aryl d-glucofuranosides as sodium-dependent glucose co-transporter 2 inhibitors.
Lin TS; Liw YW; Song JS; Hsieh TC; Yeh HW; Hsu LC; Lin CJ; Wu SH; Liang PH
Bioorg Med Chem; 2013 Nov; 21(21):6282-91. PubMed ID: 24071445
[TBL] [Abstract][Full Text] [Related]
18. Assessment of a dry extract from milk thistle (Silybum marianum) for interference with human liver cytochrome-P450 activities.
Doehmer J; Weiss G; McGregor GP; Appel K
Toxicol In Vitro; 2011 Feb; 25(1):21-7. PubMed ID: 20828605
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
20. Competitive inhibition of SGLT2 by tofogliflozin or phlorizin induces urinary glucose excretion through extending splay in cynomolgus monkeys.
Nagata T; Suzuki M; Fukazawa M; Honda K; Yamane M; Yoshida A; Azabu H; Kitamura H; Toyota N; Suzuki Y; Kawabe Y
Am J Physiol Renal Physiol; 2014 Jun; 306(12):F1520-33. PubMed ID: 24761001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]